---
title: "Dermata Therapeutics (DRMA.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DRMA.US/norm.md"
symbol: "DRMA.US"
name: "Dermata Therapeutics"
parent: "https://longbridge.com/en/quote/DRMA.US.md"
datetime: "2026-05-21T07:34:07.494Z"
locales:
  - [en](https://longbridge.com/en/quote/DRMA.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DRMA.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DRMA.US/norm.md)
---

# Dermata Therapeutics (DRMA.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.4800 | -1.65 | -1.65 | -2.67 | -4.47 |
| ROE | -116.98% | -146.27% | -141.38% | -105.37% | -207.94% |
| Revenue | - | - | - | - | - |
| Net income | -1.85M | -1.86M | -1.69M | -1.70M | -2.30M |
| Operating income | -1.93M | -1.90M | -1.76M | -1.77M | -2.34M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 7.47M | 7.86M | 5.07M | 6.64M | 10.01M |
| Leverage | 1.16 | 1.26 | 1.28 | 1.18 | 1.37 |
| BVPS | 1.59 | 2.34 | 4.69 | 8.80 | 12.10 |
| Turnover | - | - | - | - | - |
| Cash & STI | 6.95M | 7.52M | 4.66M | 6.48M | 9.72M |
| Inv & Rec | 93091.00 | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -6.95M | -7.52M | -4.66M | -6.48M | -9.72M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -2.48M | -1.33M | -1.80M | -2.69M | -1.93M |
| Investing CF | - | - | - | - | - |
| Financing CF | 1.90M | 4.19M | -12988.00 | -547857.00 | 8.49M |
| Free CF | -1.97M | -563704.00 | -1.23M | -2.62M | -607618.00 |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |